New drug revestive tracked for safety in short bowel patients
NCT ID NCT05023382
First seen Apr 14, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study monitors side effects and how well Revestive (teduglutide) controls symptoms in 250 people with short bowel syndrome. Participants receive injections under the skin as part of their regular care, and doctors watch for any problems over 36 months. The goal is to understand the drug's real-world safety and its effect on reducing the need for intravenous nutrition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.